Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
On Thursday, Citizens JMP analysts reiterated their Market Outperform rating and maintained a $25 price target for Altimmune stock (NASDAQ: NASDAQ:ALT), significantly above the current trading price of $5.49. According to InvestingPro data, analyst targets range from $6 to $28, with five analysts recently revising their earnings expectations upward for the upcoming period. The decision comes as Altimmune prepares to showcase its drug pemvidutide in an oral presentation scheduled for Saturday, June 22. The presentation will highlight cardio-inflammatory lipidomic analyses related to the drug.
While specific details of the presentation remain under embargo until Friday, June 13, Altimmune has previously shared data indicating that pemvidutide reduces lipid species linked to systemic inflammation and cardiovascular disease in obese, non-diabetic individuals. This aligns with the company’s ongoing research efforts to explore the drug’s potential benefits. The company maintains a strong financial position with more cash than debt and a healthy current ratio of 15.85, providing ample resources for its research initiatives.
In addition to the oral presentation, Altimmune plans to present three posters on pemvidutide. These posters will focus on the drug’s effectiveness in reducing visceral adipose tissue mass, its impact on cardiovascular risk, and its role in reverse cholesterol transport.
A significant upcoming event for Altimmune is the anticipated release of Phase 2b IMPACT data in MASH (Metabolic Associated Steatohepatitis), expected later this month. This data release is seen as a key catalyst for the company’s stock performance.
Altimmune continues to advance its research and development efforts, with pemvidutide playing a central role in its pipeline. The company’s focus on addressing cardiovascular and metabolic health issues through innovative treatments remains a priority.
In other recent news, Altimmune reported its first-quarter 2025 financial results, showing a narrower-than-expected loss with earnings per share of -$0.26, surpassing analyst expectations of -$0.38. The company generated $5 million in revenue for the quarter. Altimmune has also commenced a Phase 2 trial for its drug pemvidutide in treating Alcohol Use Disorder (AUD), enrolling the first subject under the guidance of Principal Investigator Dr. Henry Kranzler. Piper Sandler maintained an Overweight rating for Altimmune, with a $25 price target, highlighting the potential of pemvidutide to close the valuation gap in the NASH market. Meanwhile, Stifel analysts reiterated their Buy rating for Altimmune, with a price target of $18, expressing optimism about pemvidutide’s prospects in the MASH market. Altimmune is preparing to share topline data from its Phase 2b IMPACT trial for pemvidutide in MASH in the second quarter of 2025. Additionally, the company plans to begin enrollment for a Phase 2 trial for alcohol liver disease (ALD) in the third quarter of 2025. Altimmune raised $35 million through an ATM facility in the first quarter of 2025, further strengthening its financial position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.